Core Viewpoint - The article discusses the revolutionary impact of GLP-1 receptor agonists in obesity treatment, highlighting recent advancements in combining these drugs with NMDA receptor antagonists to enhance weight loss effects [6][8][14]. Summary by Sections GLP-1 Receptor Agonists - In 2021, the FDA approved semaglutide, a GLP-1 receptor agonist, for long-term weight management in obese and overweight adults, showing an average weight reduction of 15% with weekly injections [6]. - GLP-1 receptor agonists were initially approved for type 2 diabetes treatment, with their weight loss effects discovered during early clinical trials [8]. Innovative Combination Therapy - Researchers from Copenhagen University proposed a novel approach by combining GLP-1 receptor agonists with NMDA receptor-targeting drugs to achieve a dual weight loss effect [8]. - NMDA receptors play a significant role in appetite regulation, and previous studies have shown that NMDA receptor antagonists can induce anorexia and weight loss in mice [11]. Experimental Findings - In experiments with diet-induced obese mice, the new GLP-1–MK-801 compound resulted in a remarkable weight reduction of 23.2%, outperforming traditional calorie restriction methods [13]. - The compound maintained metabolic rates comparable to obese mice, addressing the common issue of metabolic compensation during weight loss [13]. Safety and Future Research - The safety evaluation of GLP-1–MK-801 indicated no severe adverse reactions in mice, supporting further development of this innovative drug [14]. - Future studies are needed to assess the long-term effects and safety of GLP-1–MK-801, with the potential to become a more powerful treatment option than existing weight loss medications [14]. Current GLP-1 Weight Loss Drugs - A list of GLP-1 weight loss drugs currently in various clinical stages includes: - Mounjaro (Tirzepatide) - FDA approved - Wegovy (Semaglutide) - FDA approved - Saxenda (Liraglutide) - FDA approved - Several others in clinical trials [15].

Group 1: Top Net Buy Companies - The top net buy company is Pop Mart (9992.HK) with a net buy amount of 30.56 billion CNY and a change in holdings of 11,095,857 shares[8] - Xiaomi Group (1810.HK) follows with a net buy amount of 29.88 billion CNY and a change in holdings of 65,019,122 shares[8] - China Mobile (0941.HK) ranks third with a net buy amount of 23.84 billion CNY and a change in holdings of 27,952,291 shares[8] Group 2: Top Net Sell Companies - The top net sell company is SMIC (0981.HK) with a net sell amount of -63.04 billion CNY and a change in holdings of -91,228,489 shares[9] - Alibaba (9988.HK) follows with a net sell amount of -40.16 billion CNY and a change in holdings of -26,011,949 shares[9] - Tencent Holdings (0700.HK) ranks third with a net sell amount of -27.79 billion CNY and a change in holdings of -4,569,909 shares[9] Group 3: Industry Distribution - The report highlights significant net buying in the consumer discretionary sector, particularly in companies like Pop Mart and Meituan[11] - The technology sector shows notable net selling, with companies like SMIC and Tencent experiencing substantial outflows[11] - Financial services also see mixed activity, with both buying and selling observed in major banks like ICBC and CMB[11]

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2][47]. Core Insights - The report highlights that the medical device procurement is gradually reflecting principles of "stabilizing clinical needs, ensuring quality, preventing collusion, and countering price wars" [6][30]. - The report suggests that the recent adjustments in procurement rules indicate a shift towards a more moderate approach, focusing on clinical needs and product quality rather than solely on low prices [6][30]. - The report emphasizes the potential for long-term development in the domestic medical device industry as procurement becomes more reasonable [6][30]. Summary by Sections Industry Overview - The closing index for the medical and biological sector is 8583.87, with a 52-week high of 9323.49 and a low of 6764.34 [2]. Market Performance - During the week of October 13-17, 2025, the A-share medical and biological sector fell by 2.48%, underperforming the CSI 300 index by 0.26 percentage points but outperforming the ChiNext index by 3.23 percentage points [7][36]. - The Hang Seng Healthcare Index decreased by 5.85%, underperforming the Hang Seng Index by 1.88 percentage points [7][36]. Industry Opinions and Investment Recommendations 1. **Innovative Drugs**: The innovative drug sector is experiencing adjustments, with a recommendation to maintain or increase positions based on long-term industry development logic. Key companies to watch include Innovent Biologics, 3SBio, and others [8][21]. 2. **Medical Devices**: The report notes that the National Medical Insurance Administration's recent procurement documents aim to optimize price differences and control "anchor points," indicating a move away from simply selecting the lowest bid [8][29]. 3. **Research Services**: The report expresses optimism about investment opportunities in the research services sector, particularly for companies with strong competitive advantages [26]. Sector Valuation - As of October 17, 2025, the overall valuation of the medical sector (TTM) is 30.03, a decrease of 0.84 from the previous week. The sector's valuation premium over the CSI 300 index is 123.96%, down by 4.90 percentage points [43].

Core Insights - The A-share pharmaceutical sector is showing signs of recovery, with significant inflows into representative ETFs, particularly in the CXO segment, indicating strong buying interest [1][7] - The Hong Kong innovation drug ETF (520880) has been trading at a high premium, reflecting robust buying activity, with over 125 million yuan entering the market for low absorption last week [5][7] - The pharmaceutical sector is experiencing mixed performance, with some stocks like Kelun Pharmaceutical and Baillie Gifford rising over 2%, while others like Pianzihuang faced pressure post-earnings [3][5] Group 1: Market Performance - The A-share medical sector is rebounding, with notable gains in CXO stocks, exemplified by WuXi AppTec's 3% rebound and the largest medical ETF (512170) seeing a peak premium of 1% during trading [1][3] - The only drug ETF in the market (562050) is stabilizing near water level, with frequent premiums observed in the market [3] - The Hong Kong innovation drug ETF (520880) opened over 1% higher but quickly fell below water before recovering, with major stocks like BeiGene rising over 3% while others like CanSino Biologics dropped over 2% [5][7] Group 2: Investment Strategies - Analysts suggest that the innovation drug sector may be entering a configuration window, with multiple catalysts expected in Q4, including major industry conferences and positive Q3 earnings expectations [7] - Investment strategies are focusing on two main lines: identifying stocks with strong Q3 earnings and continuing to explore innovative drugs in preparation for a potential market rebound [7][8] - The Hong Kong innovation drug ETF (520880) is characterized by 100% investment in innovative drug companies, while the largest medical ETF (512170) includes a mix of medical devices and services [8][9]

Core Viewpoint - The announcement highlights the collaboration between Shanghai Jinmant Biotech Co., Ltd. and Jiangsu Kanion Pharmaceutical Co., Ltd. for the development of JSKN003, a targeted HER2 bispecific antibody-drug conjugate, which has received breakthrough therapy designation from the National Medical Products Administration for treating HER2-positive advanced colorectal cancer patients who have failed previous treatments [1] Group 1 - The drug JSKN003 is specifically indicated for use as a monotherapy in patients with HER2-positive advanced colorectal cancer who have previously failed treatments with oxaliplatin, fluorouracil, and irinotecan [1] - The breakthrough therapy designation signifies the potential of JSKN003 to offer significant benefits over existing therapies for the targeted patient population [1]

Core Insights - The company, Shiyao Group, announced that its subsidiary, Shanghai Jinmant Biotech Co., Ltd., has received breakthrough therapy designation from the National Medical Products Administration (NMPA) for JSKN003, a targeted HER2 bispecific antibody-drug conjugate, for the treatment of HER2-positive advanced colorectal cancer patients who have failed previous treatments with oxaliplatin, fluorouracil, and irinotecan [1][4] Industry Context - Colorectal cancer is one of the most common malignancies globally, with 1.9262 million new cases and 903,900 deaths reported in 2022, ranking third in incidence and second in mortality among all cancers [2] - In China, colorectal cancer has a high incidence rate, second only to lung cancer, with over 500,000 new cases annually, and the number is rising [2] - Current approved treatments for HER2-positive advanced colorectal cancer patients who have failed previous therapies include regorafenib, fruquintinib, and trifluridine/tipiracil, but these have limited efficacy, with median progression-free survival (mPFS) of only 2-3.7 months and median overall survival (mOS) of 7-10 months [2] Clinical Research Findings - Preliminary clinical research results for JSKN003 show significant efficacy and good safety in the target patient population, with an objective response rate (ORR) of 61.9% and a disease control rate (DCR) of 95.2% among patients who had at least one tumor efficacy assessment [3] - The median progression-free survival (mPFS) for colorectal cancer patients treated with JSKN003 was reported at 13.77 months, with a median duration of response (mDoR) of 12.06 months [3] - Safety data indicated that only 14.0% of patients experienced grade 3 or higher treatment-related adverse events (TRAEs), and no TRAEs led to treatment discontinuation or death [3] Regulatory Developments - JSKN003 has received its second breakthrough therapy designation, previously granted for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer [4] - The ongoing clinical studies for JSKN003 in China include multiple Phase II and III trials for various solid tumors, including breast cancer, ovarian cancer, and gastric cancer, which will expedite the product's development and review process [4]

Core Viewpoint - The announcement highlights the breakthrough therapy designation granted to JSKN003, a targeted HER2 bispecific antibody-drug conjugate, for treating HER2-positive metastatic colorectal cancer patients who have failed previous treatments [1][4]. Group 1: Company Developments - Shanghai Jinmant Biotech, a subsidiary of the company, collaborates with Jiangsu Hengrui Medicine Co., Ltd. to develop JSKN003 [1]. - JSKN003 has received its second breakthrough therapy designation, previously granted for treating platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer [4]. - The ongoing clinical studies for JSKN003 include multiple Phase II and III trials for treating breast cancer, ovarian cancer, and gastric cancer in China [4]. Group 2: Industry Context - Colorectal cancer is one of the most common malignancies globally, with 1.9262 million new cases and 903,900 deaths reported in 2022, ranking third in incidence and second in mortality among all cancers [2]. - In China, colorectal cancer has a high incidence rate, with over 500,000 new cases annually, making it the second most common cancer after lung cancer [2]. - Current approved treatments for HER2-positive metastatic colorectal cancer in China show limited efficacy, with median progression-free survival (mPFS) of only 2-3.7 months and median overall survival (mOS) of 7-10 months [2]. Group 3: Clinical Research Findings - Preliminary clinical research results for JSKN003 indicate significant efficacy and safety in treating HER2-positive metastatic colorectal cancer, with an objective response rate (ORR) of 61.9% and disease control rate (DCR) of 95.2% among patients who had at least one tumor efficacy assessment [3]. - The median progression-free survival (mPFS) for colorectal cancer patients treated with JSKN003 was reported at 13.77 months, with a median duration of response (mDoR) of 12.06 months [3]. - Safety data from the Phase II recommended dose cohort showed that only 14.0% of patients experienced grade 3 or higher treatment-related adverse events (TRAEs), with no treatment-related deaths reported [3].

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966.HK) announced that its collaboration with Shanghai Jinmant Biotech Co., a subsidiary of CSPC Pharmaceutical Group (01093.HK), has led to the breakthrough therapy designation from CDE for JSKN003, aimed at treating HER2+ advanced colorectal cancer (CRC) patients who have failed prior treatments with oxaliplatin, fluorouracil, and irinotecan [1] Group 1 - JSKN003 has previously received breakthrough therapy designation from CDE in March 2025 for treating PROC, with no restrictions on HER2 expression levels [1]

Core Viewpoint - The latest shareholder equity disclosure for CSPC Pharmaceutical Group (01093) was conducted on October 20, 2025, indicating changes in shareholding among institutional investors [1]. Group 1: Shareholding Changes - Cai Dongchen increased his holdings in CSPC Pharmaceutical Group from 2.839 billion shares to 2.842 billion shares, representing a holding percentage of 24.67% in the latest disclosure compared to 24.64% previously [2].

自願公告 JSKN 003於中國再次獲授予突破性治療認定 用於治療HER2陽性晚期結直腸癌患者 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 在 2025 年 美 國 臨 床 腫 瘤 學 會 (ASCO ) 年 會 上 ， 一 項「 JSKN 003 單 藥 治 療 晚 期 HER2 高 表 達 （ IHC3 + ）胃腸道腫瘤患者的兩項臨床研究匯總分析」被發表。該項匯總分析包括在澳大利亞 進行的I期臨床研究(JSKN 003 -101)和在中國進行的I / II期臨床研究(JSKN 003 -102)。截至2025 年2 月 28 日 ，兩項 研究 共入組 50 例 HER2高 表達 的晚期 胃腸道 腫瘤 患者（ 其 中23 例為結 直腸 癌 ），其中38 %的患者既往接受過≥ 3線抗腫瘤治療。初 ...